cabozantinib
exelixis
['advanced uc', 'atlantis', 'cabozantinib', ' uc,(-ucsd),(-ucsf),']
rob jones conclusion on atlantis trial was as honest as could be: though underpowered, this study does not support further investigation
cabozantinib alone as a maintenance therapy after platinum-based
chemotherapy in unselected patients with advanced uc . #asco22
Oncologista clínico, CEO do Grupo SOnHe, em Campinas. e sócio-proprietário da BIO Education. Medicina Baseada em Valores, farmacoeconomia e custo-efetividade